Research Topics
Genomes and GenesSpecies | Jayant A TalwalkarSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trialJayant A Talwalkar
Division of Gastroneterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Dig Dis Sci 51:1985-91. 2006..Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events...
Primary sclerosing cholangitisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
Inflamm Bowel Dis 11:62-72. 2005..Liver transplantation remains the only successful treatment option for patients with advanced liver disease from PSC. A diagnosis of PSC should be considered among individuals with IBD and elevated serum liver biochemical tests...
An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosisJayant A Talwalkar
Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Am J Med 116:759-66. 2004..In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues...
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acidJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Clin Gastroenterol 39:168-71. 2005..Mycophenolate mofetil (MMF) is an immunosuppressive medication that inhibits T and B lymphocyte proliferation. The aim of this investigation was to determine the safety and estimated efficacy of MMF in patients with PBC...
An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascitesJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Clin Gastroenterol Hepatol 1:474-9. 2003..The evidence-based medicine concepts have been expanded from previous articles, and examples from the hepatology literature have been used...
Antifibrotic therapies--emerging biomarkers as treatment end pointsJayant A Talwalkar
Center for Advanced Imaging Research, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA
Nat Rev Gastroenterol Hepatol 7:59-61. 2010..This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis...
Influence of recent advances in medical management on clinical outcomes of cirrhosisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Mayo Clin Proc 80:1501-8. 2005....
Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysisJayant A Talwalkar
Transplant Center, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:431-5. 2003..To determine the level of association between minimal listing criteria (MLC) recognition and outcomes associated with waiting list registration for liver transplantation (LT)...
Tacrolimus for the treatment of primary sclerosing cholangitisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Liver Int 27:451-3. 2007..Results from a pilot investigation with tacrolimus for primary sclerosing cholangitis (PSC) demonstrated biochemical improvement without excessive drug toxicity. To date, no confirmatory study has been performed...
Cost-effectiveness of treating esophageal varicesJayant A Talwalkar
Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Clin Liver Dis 10:679-89, xi. 2006..Recently, several economic analyses have been developed to answer these questions and identify gasps in knowledge. This article provides an overview of results from these studies and explores areas in need of future investigation...
Medical and economic impact of autoimmune hepatitisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, S W Rochester, MN 55905, USA
Clin Liver Dis 6:649-67. 2002..As a result, the ability to plan for disease management strategies in AIH that require the allocation of scarce resources will be feasible...
Shall we bury the sword? Imaging of hepatic fibrosisJayant A Talwalkar
Advanced Liver Diseases Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Gastroenterology 131:1669-71. 2006
Magnetic resonance imaging of hepatic fibrosis: emerging clinical applicationsJayant A Talwalkar
Advanced Liver Diseases Study Group, Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
Hepatology 47:332-42. 2008..hepatology 2007.)...
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acidPhunchai Charatcharoenwitthaya
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Dig Dis Sci 55:476-83. 2010..2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA...
Mycophenolate mofetil for the treatment of primary sclerosing cholangitisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 SW First Street, Rochester, MN 55905, USA
Am J Gastroenterol 100:308-12. 2005..In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC...
Natural history of pruritus in primary biliary cirrhosisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Clin Gastroenterol Hepatol 1:297-302. 2003..No significant risk reduction in developing pruritus with UDCA therapy was observed compared to placebo-treated patients. The long-term administration of rifampin for refractory pruritus is associated with occasional hepatotoxicity...
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomesMarina G Silveira
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Gastroenterol 102:1244-50. 2007..Patients with PBC should receive ursodeoxycholic acid (UDCA); the role of and response to additional immunosuppressive therapy are unknown when AIH overlaps PBC...
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varicesRoman E Perri
Advanced Liver Diseases Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN 55905, USA
Hepatology 47:1587-94. 2008..CONCLUSION: Abdominal CT as the initial screening test for varices could be cost-effective. CT also permits evaluation of extra-luminal pathology that impacts management...
Octreotide therapy for advanced hepatocellular carcinomaWilco A Slijkhuis
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Clin Gastroenterol 39:333-8. 2005..In conclusion, although occasional patients appear to have stable disease on long-acting octreotide therapy, overall the beneficial response in terms of time to tumor progression and survival is limited...
Dynamic postprandial hepatic stiffness augmentation assessed with MR elastography in patients with chronic liver diseaseMeng Yin
Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
AJR Am J Roentgenol 197:64-70. 2011....
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastographyJun Chen
Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
Radiology 259:749-56. 2011....
Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertensionJayant A Talwalkar
Advanced Liver Diseases Study Group, Department of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, USA
AJR Am J Roentgenol 193:122-7. 2009..The purposes of this study were to determine the feasibility of measuring spleen stiffness with MR elastography and to prospectively test the technique in healthy volunteers and in patients with compensated liver disease...
Assessment of hepatic fibrosis with magnetic resonance elastographyMeng Yin
Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Clin Gastroenterol Hepatol 5:1207-1213.e2. 2007....
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring systemJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Am J Gastroenterol 97:1191-7. 2002..Applicability of the revised IAHG scoring system, however, remains questionable, as nearly 20% of PBC patients will be classified with probable AIH overlap...
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantationPhunchai Charatcharoenwitthaya
Miles and Shirley Fitterman Center for Digestive Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Liver Transpl 13:1236-45. 2007..In this short period of treatment, UDCA was not associated with improved patient and graft survival compared to untreated patients...
Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapyKonstantinos N Lazaridis
Center for Basic Research in Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Clin Gastroenterol 41:494-500. 2007....
Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequenceJason T Lewis
Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA
Am J Surg Pathol 31:907-13. 2007..The strong correlation between gallbladder dysplasia/adenocarcinoma and bile duct dysplasia/CC supports the concept of a neoplastic "field effect" along the intrahepatic and extrahepatic biliary tract in PSC...
Risk factors for mortality after surgery in patients with cirrhosisSwee H Teh
Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minnesota, USA
Gastroenterology 132:1261-9. 2007..The aim of this study was to determine the risk factors for postoperative mortality in patients with cirrhosis...
Noninvasive tools to assess hepatic fibrosis: ready for prime time?Paul A Schmeltzer
Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Gastroenterol Clin North Am 40:507-21. 2011....
Primary biliary cirrhosisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Lancet 362:53-61. 2003..Despite advances in understanding of the disease, it remains one of the major indications for liver transplantation worldwide...
"Will all liver transplantation patients eventually die from cancer?"William Sanchez
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55901, USA
J Hepatol 44:13-8. 2006
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitisJayant A Talwalkar
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Hepatology 40:39-45. 2004..30 US dollars would be required. In conclusion, MRC has comparable accuracy to ERCP and results in cost savings when used as the initial test strategy for diagnosing PSC...
Diagnostic evaluation of nonalcoholic fatty liver diseaseLeon A Adams
Division of Gastroenterology and Hepatology, Mayo Clinic and College of Medicine, Rochester, MN 55905, USA
J Clin Gastroenterol 40:S34-8. 2006..Clinical features, particularly diabetes, obesity, and older age, can aid in stratifying patients at risk for advanced fibrosis but are not sufficiently accurate to replace liver biopsy...
Abdominal magnetic resonance elastographyMeng Yin
Department of Radiology, Mayo Clinic, Rochester, MN, USA
Top Magn Reson Imaging 20:79-87. 2009..Steady technical progress in developing practical protocols for applying MRE in the abdomen and the pelvis provides opportunities to explore many other potential applications of this emerging technology...
MR elastography of liver tumors: preliminary resultsSudhakar K Venkatesh
Department of Radiology, Mayo Clinic and Foundation, 200 First St SW, Opus Bldg, Rochester, MN 55905, USA
AJR Am J Roentgenol 190:1534-40. 2008..The purpose of this study was to evaluate the potential value of MR elastography (MRE) in the characterization of solid liver tumors...
Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysisCorlan O Adebajo
Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Liver Transpl 18:323-31. 2012..The detection of significant fibrosis is more accurate for these patients versus patients whose native liver is chronically infected with HCV...
Motion - all patients with NASH need to have a liver biopsy: arguments for the motionJayant A Talwalkar
Mayo Clinic and Foundation, Rochester 55902, USA
Can J Gastroenterol 16:718-21. 2002..Only histological examination can establish the diagnosis of NASH, grade its severity, determine the prognosis and guide treatment...
Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimensAlexander Meves
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Acad Dermatol 55:642-6. 2006..We conclude that early testing of skin biopsy specimens using fluorescent in situ hybridization in sex-mismatched patients with orthotopic liver transplantation can serve as an early diagnostic tool for graft-versus-host disease...
Palliative care for patients with end-stage liver disease ineligible for liver transplantationWilliam Sanchez
Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55901, USA
Gastroenterol Clin North Am 35:201-19. 2006..Medicare provides a hospice benefit for patients with ESLD, and referral to a hospice is appropriate for patients with an expected survival of 6 months or less...
Diagnosis and staging of hepatocellular carcinomaJayant A Talwalkar
William J. von Liebig Transplantation Center, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Gastroenterology 127:S126-32. 2004..Additional diagnostic techniques based on cytological advances, genomics, and proteomics are needed for the diagnosis and staging of this highly malignant neoplasm...
Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis CStanley S Liu
Viral Hepatitis Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
J Clin Gastroenterol 44:e178-85. 2010..The aim of our study was to examine the influence of antidepressant treatment and whether this improves the likelihood of completing therapy...
Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysisJayant A Talwalkar
Advanced Liver Disease Study Group, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Clin Gastroenterol Hepatol 5:1214-20. 2007..The aims of this study were to perform a systematic review and meta-analysis of diagnostic accuracy studies comparing ultrasound-based transient elastography with liver biopsy for hepatic fibrosis...
Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levelsSuzette J Bielinski
Division of Epidemiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Mayo Clin Proc 86:606-14. 2011....
Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatmentJayant A Talwalkar
Advanced Liver Diseases Study Group, Mayo Clinic, Rochester, Minnesota 55905, USA
Gastroenterology 141:1673-9. 2011..We documented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe portopulmonary hypertension (POPH) and determined the association between large shunts and response to treatment...
Enhancing the role of internal medicine subspecialty societies in defining quality of careJayant A Talwalkar
Mayo Clinic College of Medicine, USA
Minn Med 89:42-5. 2006
Determining the extent of quality health care for hospitalized patients with cirrhosisJayant A Talwalkar
Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Hepatology 42:492-4. 2005..These results contribute to defining the natural course and prognosis of decompensated HCV-related cirrhosis...
Celiac disease-associated autoimmune cholangitisRobert E Sedlack
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Am J Gastroenterol 97:3196-8. 2002..CD should be considered in all patients diagnosed with autoimmune cholangitis as a gluten-free diet may avoid the need for immunosuppressive therapy in affected patients...
Practice variation in treatment of primary biliary cirrhosis and effect on clinical outcomesJayant A Talwalkar
Hepatology 47:1428. 2008
Markov models in primary biliary cirrhosisJayant A Talwalkar
Gastroenterology 123:1750-1. 2002
Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosisJayant A Talwalkar
Liver Int 28:761-3. 2008
Determining the nature and impact of fatigue after liver transplantationJayant A Talwalkar
Liver Transpl 12:899-901. 2006
Prophylaxis with beta blockers as a performance measure of quality health care in cirrhosisJayant A Talwalkar
Gastroenterology 130:1005-7. 2006
Functional hepatic imaging and disease recurrence after liver transplantationJayant A Talwalkar
Liver Transpl 12:1744-6. 2006
Economic impact of hospitalization for end-stage liver diseaseJayant A Talwalkar
Am J Gastroenterol 97:1562; author reply 1562-3. 2002
Acute graft-versus-host disease after liver transplantationM Peter Ghali
Transplantation 83:365-6. 2007
Role of computerized image morphometry for assessing noninvasive methods to detect hepatic fibrosisJayant A Talwalkar
Clin Gastroenterol Hepatol 6:958-9. 2008
Elastography for detecting hepatic fibrosis: options and considerationsJayant A Talwalkar
Gastroenterology 135:299-302. 2008
Analysis of factors that predict alcohol relapse following liver transplantationSameer Jauhar
University of Glasgow, Scotland, UK
Liver Transpl 10:408-11. 2004..03). Further prospective studies are needed to examine this association in greater detail to provide targeted treatment for alcoholism both before and after liver transplantation...
Polluting the pathogenesis of primary biliary cirrhosisJayant A Talwalkar
Hepatology 43:398-400. 2006
Methodologic issues with transfer of ultrasound-based transient elastography into clinical practiceJayant A Talwalkar
J Hepatol 47:301-2. 2007
Risk of lymphoma in primary biliary cirrhosisChakri Panjala
Division of Gastroenterology Hepatology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA
Clin Gastroenterol Hepatol 5:761-4. 2007..Therefore, we sought to describe the frequency, clinical spectrum, and outcomes among patients with PBC and a concomitant diagnosis of lymphoma...
